Stay updated on Biomarker Therapy for AR-V7+ Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Biomarker Therapy for AR-V7+ Prostate Cancer Clinical Trial page.

Latest updates to the Biomarker Therapy for AR-V7+ Prostate Cancer Clinical Trial page
- Check6 days agoChange DetectedThe clinical trial record for STARVE-PC is displayed, describing a completed phase 2 study of nivolumab and ipilimumab, with or without enzalutamide, for AR-V7-expressing metastatic prostate cancer. The record includes participant eligibility, treatment arms, outcome measures, investigators, publications, and study documents.SummaryDifference64%

- Check13 days agoChange DetectedThe footer shows a newer site revision number, while the page continues to display a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check27 days agoChange DetectedThe footer site revision changes from v3.7.1 to v3.7.2 on the 403 Forbidden page.SummaryDifference0.2%

- Check34 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1, while the page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the previously visible study record content. This blocks access to the study overview, eligibility details, and contacts on the ClinicalTrials.gov record.SummaryDifference21%

- Check62 days agoChange DetectedRevision 3.7.0 replaces 3.6.6 for the page, signaling a new version of the page's documentation. It represents a maintenance update rather than a substantive change to the study details.SummaryDifference0.1%

Stay in the know with updates to Biomarker Therapy for AR-V7+ Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Biomarker Therapy for AR-V7+ Prostate Cancer Clinical Trial page.